Spinal Muscular Atrophy Clinical Trial
Official title:
An Open Label Multi-part First-in-human Study of Oral LMI070 in Infants With Type 1 Spinal Muscular Atrophy
Verified date | April 2023 |
Source | Novartis |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
An open-label, multi-part, first-in-human study of oral branaplam in infants with Type 1 spinal muscular atrophy. The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and efficacy after 13 weeks; and to estimate the Maximum Tolerated Dose (MTD) of orally administered branaplam; and to identify the dose that is safe for long term use as well as that can provide durable efficacy optimal dosing regimen in patients with Type 1 SMA.
Status | Completed |
Enrollment | 40 |
Est. completion date | December 29, 2022 |
Est. primary completion date | December 29, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 28 Days to 182 Days |
Eligibility | Inclusion Criteria: Common for both Parts 1 and 2: - Type 1 SMA, diagnosed clinically, with symptom onset <6 months of age and genetic confirmation of mutations in both alleles of the SMN1 gene, and with SMN2 copy number of 2. - Best supportive care in place and stable for at least 14 days before screening. - Must be able to demonstrate antigravity strength in both biceps. At birth gestational age >32 weeks and body weight at birth >2 kg. - Must live within 2 hours drive of study center. Clearance should be obtained from the site investigator and sponsor if the patient resides more than 2 hours ground travel from the study center Specific for Part 1 - Age at screening between 1 and 7 months - Must have or agree to have placement of feeding tube for enteral access via nasogastric (NG), nasojejunal (NJ), percutaneous gastrostomy (PEG), or percutaneous jejunostomy (PEJ) tube for administration of branaplam (for patients in whom branaplam cannot be administered orally ; NG tube may be removed between doses). Specific for Part 2 - Age at screening between 30 and 180 days of age - Must have or agree to have placement of feeding tube for enteral access via nasogastric (NG), nasojejunal (NJ), percutaneous gastrostomy (PEG), or percutaneous jejunostomy (PEJ) tube for administration of branaplam (for the first administration only and for patients in whom branaplam cannot be administered orally; NG tube may be removed between doses). - Minimum CHOP INTEND score of 15 at baseline - Must be able to feed orally for all nutritional needs and be greater than the 2nd percentile for weight on the standard growth curves for the country of origin Exclusion Criteria: Common for both Parts 1 and 2: - Neurologic, or neuromuscular conditions other than SMA. - Anemia, leukopenia, neutropenia or thrombocytopenia - Hepatic dysfunction - Age adjusted renal dysfunction - Presence of an untreated or inadequately treated active infection requiring systemic antiviral or antimicrobial therapy at any time during the screening period. - Presence of an untreated or inadequately treated active infection requiring systemic antiviral or antimicrobial therapy at any time during the screening period. - Excluding SMA, any medically unstable condition including cardiomyopathy, hepatic dysfunction, kidney disorder, endocrine disorder, GI disorders, prematurity of <32 weeks gestation, metabolic disorders, severe respiratory compromise and significant brain abnormalities or injuries including hypoxic-ischemic encephalopathy. - Current diagnosis of cardiac and/or vascular abnormalities or ECG abnormalities - Acute or ongoing medical condition that, according to the Site Investigator and discussed with sponsor, would interfere with the conduct and assessments of the study. Examples are medical disability other than SMA that would interfere with the assessment of safety or would compromise the ability of the subject to undergo study procedures including be assessed by CHOP INTEND motor scale, changes in hematologic parameters or gastrointestinal dysfunction that would compromise the ability of adequate assessment of safety Specific for Part 1 - Use of other investigational drugs within 14 days. - Intractable seizure disorder (other than inactive febrile seizures). - Persistent (in the opinion of the Investigator) hypoxemia (O2 saturation awake <92% or O2 saturation asleep <91%, without ventilation support) or requiring oral suctioning >2 per day, or presence of a tracheostomy. Specific for Part 2 - Use of nusinersen or gene transfer at any time or other investigational drugs within 14 days. - Intractable epilepsy - Persistent (in the opinion of the Investigator) hypoxemia (O2 saturation awake <92% or O2 saturation asleep <91%, without ventilation support), or presence of a tracheostomy. |
Country | Name | City | State |
---|---|---|---|
Belgium | Novartis Investigative Site | Gent | |
Belgium | Novartis Investigative Site | Leuven | |
Bulgaria | Novartis Investigative Site | Sofia | |
Denmark | Novartis Investigative Site | Copenhagen | |
Germany | Novartis Investigative Site | Essen | |
Italy | Novartis Investigative Site | Milano | MI |
Italy | Novartis Investigative Site | Roma | RM |
Poland | Novartis Investigative Site | Warsaw | |
Poland | Novartis Investigative Site | Wroclaw | |
Russian Federation | Novartis Investigative Site | Ekaterinburg | |
Russian Federation | Novartis Investigative Site | Moscow | |
Russian Federation | Novartis Investigative Site | Moscow | |
Russian Federation | Novartis Investigative Site | Saint Petersburg | |
Russian Federation | Novartis Investigative Site | Volgograd |
Lead Sponsor | Collaborator |
---|---|
Novartis Pharmaceuticals |
Belgium, Bulgaria, Denmark, Germany, Italy, Poland, Russian Federation,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of participants with adverse events (AEs), serious adverse events (SAEs) | Participants are monitored for safety throughout the study | 13 weeks | |
Primary | Number of participants with adverse events (AEs), serious adverse events (SAEs) | Participants are monitored for safety throughout the study | 52 weeks | |
Secondary | Change from baseline in length | To evaluate the effect of branaplam on length in cm | Part 1 Screening, Days 1, 8 to 85. Extended treatment periods: every 4 weeks and at the end of study. Part 2: Screening, days 1 through 358 and end of study. | |
Secondary | Change from baseline in pulse oximetry | To evaluate the effect of branaplam on respiratory function by measurement of Pulse oximetry in percentage (%) of oxygen saturation | Part 1 Screening, Days 1, 8 to 85. Extended treatment periods: every 4 weeks and at the end of study. Part 2: Screening, days 1 through 358 and end of study. | |
Secondary | Change from baseline in Hammersmith Infant Neurology Examination (HINE) section 2 | To evaluate the effect of branaplam on infant motor development using HINE section 2 | Part 1 Screening, Days 1, 8 to 85. Extended treatment periods: every 4 weeks and at the end of study. Part 2: Screening, days 1 through 358 and end of study. | |
Secondary | Pharmacokinetic: AUC | To evaluate branaplam pharmacokinetics in plasma after single and repeated doses of branaplam by determination of AUC. | Parts 1 and 2: Day 1 (Pre-dose + 1, 2, 4, 8 & 24 hours post-dose), Days 2, 3, 5, 8, 29. Part 1: Day 43. Part 2: Day 57, 57, 92 (Pre-dose + 4 & 24 hours post-dose), 94, 99, 274 (Pre-dose + 4 & 24 hours post-dose), 276, 281 | |
Secondary | In addition to the above for Part 2 - Change from baseline in feeding status | To evaluate the efficacy of branaplam on preservation of oral feeding | Baseline, Day 15, Day 36, Day 57, Day 88 + End of Study | |
Secondary | In addition to the above for Part 2 - Changes in Ulnar Nerve Compound Motor Action Potential (CMAP) from baseline | To evaluate the efficacy of branaplam on Ulnar and Peroneal Nerve Compound Motor Action Potentials (CMAPs) in terms of % increase from baseline | Baseline, Day 88 + End of Study | |
Secondary | In addition to the above for Part 2 - Changes from baseline on the ability to site without support | To evaluate the efficacy of branaplam on the ability to sit without support | 52 weeks | |
Secondary | Change from baseline in weight | To evaluate the effect of branaplam on weight in kilograms | Screening, Day 1, Day 8 to Day 85. Extended treatment periods: every 4 weeks and at the End of Study | |
Secondary | Change from baseline in head circumference | To evaluate the effect of branaplam on head circumference in cm | Part 1 Screening, Days 1, 8 to 85. Extended treatment periods: every 4 weeks and at the end of study. Part 2: Screening, days 1 through 358 and end of study. | |
Secondary | Change from baseline in chest circumference | To evaluate the effect of branaplam on chest circumference | Part 1 Screening, Days 1, 8 to 85. Extended treatment periods: every 4 weeks and at the end of study. Part 2: Screening, days 1 through 358 and end of study. | |
Secondary | Change from baseline in Children's Hospital of Philadelphia Infant Neuromuscular Disorders (CHOP INTEND) | To evaluate the effect of branaplam on infant motor development using CHOP INTEND | Part 1: Baseline, Day 36, Day 85, and every 6 to 7 weeks in the extended treatment periods, and at the End of Study. Part 2: Baseline, Day 36, Day 85, Day 127, Day 176, Day 218, Day 267, Day 309, Day 358 and End of Study | |
Secondary | Change from baseline in respiratory rate | To evaluate the effect of branaplam on respiratory function by measurement of the respiratory rate | Part 1 Screening, Days 1, 8 to 85. Extended treatment periods: every 4 weeks and at the end of study. Part 2: Screening, days 1 through 358 and end of study. | |
Secondary | Change from baseline in chest circumference during quiet breathing | To evaluate the effect of branaplam on respiratory function by measurement of the chest circumference in cm during expiration and during inspiration | Part 1 Screening, Days 1, 8 to 85. Extended treatment periods: every 4 weeks and at the end of study. Part 2: Screening, days 1 through 358 and end of study. | |
Secondary | Change from baseline in paradoxical breathing | To evaluate the effect of branaplam on respiratory function by evaluation of the presence of absence of paradoxical breathing | Part 1 Screening, Days 1, 8 to 85. Extended treatment periods: every 4 weeks and at the end of study. Part 2: Screening, days 1 through 358 and end of study. | |
Secondary | Pharmacokinetic: Cmax | To evaluate branaplam pharmacokinetics in plasma after single and repeated doses of branaplam by determination of Cmax. | Parts 1 and 2: Day 1 (Pre-dose + 1, 2, 4, 8 & 24 hours post-dose), Days 2, 3, 5, 8, 29. Part 1: Day 43. Part 2: Day 57, 57, 92 (Pre-dose + 4 & 24 hours post-dose), 94, 99, 274 (Pre-dose + 4 & 24 hours post-dose), 276, 281 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04851873 -
Safety and Efficacy of Intravenous OAV101 (AVXS-101) in Pediatric Patients With Spinal Muscular Atrophy (SMA)
|
Phase 3 | |
Completed |
NCT03223051 -
Development of a Space Exploration Assessment for Children With Spinal Muscular Atrophy
|
N/A | |
Completed |
NCT04335942 -
Characterization of the Postural Habits of Wheelchair Users Analysis of the Acceptability of International Recommendations in the Prevention of Pressure Sores Risk by Using a Connected Textile Sensor
|
N/A | |
Recruiting |
NCT05794139 -
Safety and Efficacy of NMD670 in Ambulatory Adult Patients With Type 3 Spinal Muscular Atrophy
|
Phase 2 | |
Not yet recruiting |
NCT06300996 -
Spinal Cord Stimulation for the Treatment of Motor Deficits in People With Spinal Muscular Atrophy - Upper Limb
|
N/A | |
Completed |
NCT02003937 -
Aerobic Training in Patients With Spinal Muscular Atrophy Type III
|
N/A | |
Not yet recruiting |
NCT00961103 -
Motor Development and Orthoses in Spinal Muscular Atrophy (SMA)
|
N/A | |
Completed |
NCT00227266 -
Valproic Acid and Carnitine in Patients With Spinal Muscular Atrophy
|
Phase 2 | |
Completed |
NCT00374075 -
Study of Safety and Dosing Effect on SMN Levels of Valproic Acid (VPA) in Patients With Spinal Muscular Atrophy
|
Phase 1 | |
Enrolling by invitation |
NCT05539456 -
Reliability and Validity of the Turkish Version of the PedsQL 3.0 Neuromuscular Module for 2-to 4- Year-old
|
||
Recruiting |
NCT05779956 -
Personalized Medicine for SMA: a Translational Project
|
||
Recruiting |
NCT03300869 -
Natural History of Types 2 and 3 SMA in Taiwan
|
||
Recruiting |
NCT03217578 -
Neonatal Spinal Muscular Atrophy (SMA) Screening
|
||
Completed |
NCT01703988 -
An Open-label Safety, Tolerability and Dose-Range Finding Study of Multiple Doses of Nusinersen (ISIS 396443) in Participants With Spinal Muscular Atrophy
|
Phase 1/Phase 2 | |
Withdrawn |
NCT02235090 -
Study of Feasibility to Reliably Measure Functional Abilities' Changes in Nonambulant Neuromuscular Patients Without Trial Site Visiting
|
N/A | |
Completed |
NCT02123186 -
Newborn Screening for Spinal Muscular Atrophy
|
N/A | |
Completed |
NCT00756821 -
A Pilot Study of Biomarkers for Spinal Muscular Atrophy
|
N/A | |
Completed |
NCT00004771 -
Phase II Study of Leuprolide and Testosterone for Men With Kennedy's Disease or Other Motor Neuron Disease
|
Phase 2 | |
Recruiting |
NCT05366465 -
Quality of Life and Participation of the Adult With Spinal Muscular Atrophy in France
|
||
Recruiting |
NCT06310421 -
Spinal Muscular Atrophy Neonatal Screening Program
|